Polivy (polatuzumab vedotin-piiq) / Roche, Pfizer - LARVOL DELTA

Effectiveness of polatuzumab-based regimens among elderly patients with previously untreated diffuse large B-cell lymphoma: A systematic review and meta-analysis (ASH 2025) - "The Pola-R-CHP regimen showed better response, supporting its use as a frontline option in this population. The meta-analysis is ongoing; safety and long-term survival data will be updated in due course."

Retrospective data • Review • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Lung infections and clinical outcomes of diffuse large B-cell lymphoma treated with polatuzumab vedotin-based combination therapy (ASH 2025) - "The Pola+R-CHP regimen is a highly effective option for DLBCL patients. The high incidence of Pneumocystis jirovecii infection during Pola+X regimen treatment highlights the critical importance of prophylactic use of Sulfamethoxazole throughout the peri-chemotherapy period."

Clinical • Clinical data • Combination therapy • B Cell Lymphoma • Cytomegalovirus Infection • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases

Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data (ASH 2025) - "All patients received at least 3 cycles of Pola-based regimens, with the vast majority administered Pola-R-CHP, consisting of polatuzumab vedotin (1.8 mg/kg, intravenous [IV], day 1); rituximab (375 mg/m², IV day 1); cyclophosphamide (750 mg/m², IV, day 1); doxorubicin (50 mg/m², IV, day 1); and prednisone (100 mg,oral, days 1–5), repeated every 21 days. Conclusion Our findings indicate that Pola-based regimens exhibit high response rates and favorable safety profiles in newly diagnosed DLBCL patients with high-risk features in real world settings. Prospective studies with larger cohorts are needed to further validate these observations."

Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • CD5 • CD79B • TP53

Real-world use of Pola-R-CHP for untreated diffuse large B-cell lymphoma (DLBCL): A systematic literature review (ASH 2025) - P3 | "Introduction: The phase III POLARIX study (NCT03274492) demonstrated the superiority of Polatuzumab vedotin (Pola) combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) over R-CHOP, marking the first major advancement in over 20 years in first-line (1L) diffuse large B-cell lymphoma (DLBCL). This SLR analyzing currently available RWD addressing the safety and effectiveness of Pola-R-CHP for 1L DLBCL aligns with results from the POLARIX trial. Despite study and reporting heterogeneity, response rates and PFS are consistent, as are outcomes in patients older than 80 years, supporting the use of this regimen in patients with newly diagnosed DLBCL."

Clinical • Real-world • Real-world evidence • Review • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma

Optim.AI™ 2.0: Functional precision platform for identifying effective immunotherapy combinations in DLBCL (ASH 2025) - "PBMCs were added to tumor cells at a fixed effector-to-target ratio, and Optim.AI 2.0 combinatorial drug sensitivity testing plates were applied to the co-culture system, with up to 12 FDA-approved drugs, including monoclonal antibodies (rituximab, obinutuzumab), antibody-drug conjugates (polatuzumab), bispecific antibodies (epcoritamab, glofitamab), targeted small-molecule inhibitors (venetoclax, everolimus, zanubrutinib), and cytotoxic chemotherapies (gemcitabine, oxaliplatin, cyclophosphamide, doxorubicin). This study demonstrates the feasibility of Optim.AI™ 2.0, an enhanced co-culture-based platform which provides a physiologically relevant and scalable approach to functionally evaluate immunotherapy drug sets. With further validation, Optim.AI™ 2.0 holds strong potential to support clinical decision-making and expand the use of immunotherapies in DLBCL."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Sarcoma • Solid Tumor

Clinical use of genome-wide hi-c sequencing for assessment of structural variants in diffuse large B-cell lymphoma (ASH 2025) - "The patient was treated with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) but subsequently progressed through therapy. Hi-C sequencing was able to define the partner of the IGH gene rearrangements to be an intergenic region of chromosome 10, revealing that this was likely not related to the pathogenesis in this case. Furthermore, Hi-C sequencing found copy number aberrations and a tandem amplification of CD79B , a key regulator in B-cell signaling. Accordingly, this finding is associated with a more aggressive phenotype in DLBCL, as was observed in this patient."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CD79B • CLTC • IGH • MSI2 • PRKCA

Polatuzumab vedotin, zanubrutinib, rituximab, lenalidomide, and prednisone (Pola-ZR2P) as frontline immunochemotherapy in previously untreated DLBCL patients (ASH 2025) - P2 | "She had a history of arrhythmia managed with intermittent propafenone. Pola-ZR2P regimen demonstrated promising efficacy and a manageable safety profile in this cohort of previously untreated DLBCL patients. This report provides clinical evidence on the efficacy and safety of Pola-ZR2P regimen as the frontline immunochemotherapy in previously untreated DLBCL patients. Further enrollment of more patients is necessary to better clarify the effectiveness and safety of Pola-ZR2P regimen as the frontline chemotherapy in DLBCL patients."

Clinical • B Cell Lymphoma • Cardiovascular • Coronary Artery Disease • Dermatology • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastroenterology • Hematological Disorders • Hematological Malignancies • Hypertension • Immunology • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pruritus • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Septic Shock • TP53

Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma (ASH 2025) - "Introduction: Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) following at least one prior line of therapy, either as monotherapy or in combination with gemcitabine and oxaliplatin (GemOx)...Specifically, 6 patients (17.1%) had a history of bendamustine exposure, and 4 patients (11.4%) had undergone both autologous stem cell transplantation and chimeric antigen receptor T-cell therapy...Among them, the regimens included glofitamab monotherapy (28, 80.0%), glofitamab combination with bruton tyrosine kinase inhibitors (3, 8.6%), GemOx (2, 5.7%), polatuzumab vedotin (1, 2.9%) or dose-reduced ifosfamide, carboplatin and etoposide (1, 2.9%)... Our findings characterize disease features of heavily treated r/r aggressive B-cell lymphoma and real-world outcomes with glofitamab-based salvage. Even in the subgroups with adverse prognosis factors, glofitamab-based regimens still demonstrated..."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • CD4 • TP53

Glofitamab-based combinatorial therapy demonstrates high efficacy in primary refractory and early relapsed DLBCL: Real-world evidence of durable responses and immune modulation in high-risk subgroups (ASH 2025) - "Tocilizumab was administered in 8.3% (1/12)...Notably, this activation persisted without exhaustion through 6 cycles, including in CAR-T–pretreated ( n =2) and bendamustine-exposed ( n =2) subgroups, suggesting sustained modulation of the tumor immune microenvironment... Glofitamab exhibits clinically significant activity in primary refractory and early relapsed DLBCL through potent T/NK-cell engagement, inducing durable responses across high-risk subtypes. Real-world data support combinability with Polatuzumab Vedotin, PD-1 immune checkpoint inhibitor, GemOx, BTKi, or radiotherapy, warranting proactive toxicity monitoring. These findings establish glofitamab as a transformative backbone therapy for resistant DLBCL, addressing critical unmet needs via its unique immune-redirecting mechanism."

Clinical • HEOR • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Immune Modulation • Immunology • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Respiratory Diseases • CD20 • CD4 • CD5 • CD8 • TP53

Real world chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma: The Australian experience (ASH 2025) - "Pts received commercial CD19-directed CAR-T cell therapy; Axicabtagene ciloleucel (Axi-cel) or Tisagenlecleucel (Tisa-cel)...Bridging therapy was administered in 70% of pts, comprising checkpoint inhibitor 10%, immunochemotherapy 20%, corticosteroids-only 10%, polatuzumab 10% and radiotherapy 20%... Eleven pts underwent leukapheresis and were eligible for analysis; with 10 pts proceeding to CAR-T infusion. The median age of the cohort was 67 years with a male predominance (89%). 50% had primary refractory disease with 80% refractory to ≥2 prior therapies."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • T Cell Histiocyte Rich Large B Cell Lymphoma

Anti-CD19 chimeric antigen receptor T-cells therapy (CAR-T) is effective in secondary cns lymphoma (SCNSL) refractory to high-dose methotrexate (HDMTX)-based chemotherapy (ASH 2025) - " 23 pts were referred to holding: 6 partial-brain irradiation, 4 intrathecal CHT, 2 polatuzumab vedotin, 5 ibrutinib, 1 HD-ifosfamide-based CHT, 2 MATRix regimen, 1 thiotepa-based ASCT, combinations of these strategies in 2...Only one pt experienced G3-4 CRS, all CRS cases were successfully treated with tocilizumab and steroids, anakinra was used in 2 cases... Varied presentation and high aggressivity of SCNSL impede the use of a uniform treatment for these pts. SCNSL refractory to HDMTX-based polyCHT can benefit significantly from a tailored multimodal holding based on the pt's history and extension of disease. Only pts with good PS and responsive to holding therapy should be offered CAR-T to avoid superfluous toxicity."

CAR T-Cell Therapy • B Cell Lymphoma • CNS Disorders • CNS Lymphoma • Epilepsy • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Secondary Central Nervous System Lymphoma

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China (ASH 2025) - "Introduction: The landmark POLARIX study showed that Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) regimen was superior to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) in previously untreated diffuse large B-cell lymphoma (DLBCL) with IPI 2-5. This investigation represents the first multicenter study addressing real-world outcomes of IPI 0-1 DLBCL patients treated with first-line Pola-R-CHP. Our results suggested that Pola-R-CHP showed excellent effectiveness and manageable toxicities for this specific population, even among those with adverse risk factors."

Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • TP53

Effectiveness and safety profile of pola-based regimen in DLBCL Patients with high-risk factors in real world: A retrospective study in China (ASH 2025) - "Background Polatuzumab vedotin, an antibody-drug conjugate targeting CD79b, has become the standard of care (SOC) for both treatment-naive (TN) and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients, administered via the Pola-R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) and Pola-BR (bendamustine plus rituximab) regimens. Even in this high-risk population, Pola-based therapy demonstrated promising efficacy and manageable toxicity. However, detailed data on response rates and survival outcomes require further reporting following extended follow-up."

IO biomarker • Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • T Cell Histiocyte Rich Large B Cell Lymphoma • CD5 • CD79B • TP53

Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study (ASH 2025) - "In this real-world cohort of very high-risk, super-elderly DLBCL patients, the chemotherapy-free POLA-Z-R regimen demonstrated promising anti-tumor activity and a manageable safety profile. These preliminary findings suggest that this targeted combination represents a potential new therapeutic option for this frail, difficult-to-treat population. These results warrant validation in larger, prospective studies to establish the role of POLA-Z-R in the treatment algorithm for super-elderly DLBCL patients."

IO biomarker • Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Thrombosis • BCL2 • CD79B

First-line pola-R-CHP in diffuse large B cell lymphoma: A single-center real-world data analysis (ASH 2025) - "This real-world study demonstrated significantly lower CR rates with first-line Pola-R-CHP compared to POLARIX. This disparity likely reflects both the enrichment of high-risk patients (90.2% stage III-IV, 39.2% ECOG ≥ 2) and constrained PET/CT availability (predominant reliance on CT for response assessment), illustraiting the impact of socioeconomic factors in resource-limited settings where Pola use clusters within advanced populations. Caution is warranted due to potential selection bias, small sample size, and limited follow-up, extended studies are needed."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CD20 • TP53

A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China (ASH 2025) - "The Pola-R-CHP regimen demonstrated promising clinical efficacy and acceptable safety in newly diagnosed DLBCL patients. Subgroup analyses showed comparable PFS and OS outcomes between patients with and without bulky disease, suggesting that the Pola-R-CHP regimen may mitigate the adverse prognostic impact of bulky disease. These findings support Pola-R-CHP as a valuable first-line option."

Retrospective data • Alopecia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Immunology • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CD5

Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study (ASH 2025) - "Polatuzumab vedotin (Pola), an antibody-drug conjugate targeting CD79b, has demonstrated safety and efficacy when combined with bendamustine and rituximab in transplant-ineligible patients (pts) with relapsed DLBCL pts. We evaluated the safety and efficacy of Pola-ICE regimen—comprising polatuzumab vedotin, ifosfamide, carboplatin, and etoposide—with or without the addition of rituximab in R/R DLBCL pts in the real world...All patients received Pola-ICE: Pola 1.8 mg/kg (day 1), ifosfamide 4000 mg/m² (administered in two divided doses, days 1–2, with MESNA infusion), carboplatin AUC 4 (day 2), etoposide 100 mg/m² (days 1–3), repeated every 21 days up to 6 cycles... Pola-ICE, with or without rituximab, demonstrated promising efficacy with high-quality responses and manageable toxicity in heavily pretreated R/R DLBCL pts. This salvage regimen may serve as a viable option for high-risk patients, potentially enabling subsequent curative-intent therapies."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CD79B

Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study (ASH 2025) - "Treatment regimens included Pola-R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) in 30 patients, Pola-miniCHP in 4 patients, Pola-ZR (zanubrutinib, rituximab) in 6 patients, and other regimens in 2 patients. Dose-reduced chemoimmunotherapy (Pola-miniCHP) and chemo-light regimens (Pola-ZR) provided reasonable efficacy in elderly or frail patients, warranting further evaluation in larger cohorts. Keywords polatuzumab vedotin; diffuse large B-cell lymphoma; newly diagnosed; efficacy; safety"

Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Geriatric Disorders • Infectious Disease • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases

Therapeutic outcomes of glofitamab-based regimens in Chinese patients with Relapsed/Refractory B-cell lymphoma: A single-center retrospective real-world study (ASH 2025) - "Treatment regimens consisted of glofitamab monotherapy (n=10), glofitamab plus chemotherapy (n=8), and glofitamab plus polatuzumab vedotin (n=2). Glofitamab-based therapy shows superior efficacy and a manageable safety profile in Chinese R/R B-cell lymphoma patients, potentially establishing it as a preferred treatment option for this population."

IO biomarker • Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Burkitt Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Primary Central Nervous System Lymphoma • Respiratory Diseases • TP53

A real-world analysis of primary mediastinal large B-cell lymphoma: A single center study in China (ASH 2025) - "Polatuzumab vedotin, an anti-CD79b monoclonal antibody, when combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP), offers the benefits of more convenient administration and comparable safety to the R- CHOP regimen, while demonstrating reduced toxicity comparison to DA-EPOCH-R...Another patient attained CMR following R-ESHAP treatment for lymph node relapse, whereas one succumbed to CNS relapse despite receiving multiple therapies, including surgery, HD-MTX BV, selinexor, and thiotepa.5 patients received targeted therapies...Summary/Conclusion POLA-R-CHP shows potential as an efficient therapy for PMBCL. Its frontline application could enhance overall response rates while reducing treatment-related toxicity."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Nephrology • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Renal Disease • Respiratory Diseases • CD79B

Polatuzumab-vedotin in large diffuse B-cell lymphoma: A multicenter observational study from Latin America (2020–2024) (ASH 2025) - "Introduction: Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug conjugate linked to monomethyl auristatin E (MMAE), demonstrated improved progression-free survival (PFS) in the phase 3 POLARIX trial when combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) compared with R-CHOP in the frontline treatment of diffuse large B-cell lymphoma (DLBCL) (Sehn et al., 2022). To our knowledge, this is one of the first real-world analyses of polatuzumab vedotin (Pola)-based regimens in Latin America. In a resource-constrained setting with heterogeneous treatment strategies, Pola demonstrated meaningful clinical activity across multiple lines of therapy. Response rates and 1-year overall survival were comparable to those reported in the phase 2 trial by (Sehn et al.,2022) and exceeded outcomes from other real-world cohorts in relapsed/refractory DLBCL."

Clinical • IO biomarker • Observational data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • BCL2 • BCL6 • CD79B • TP53

The efficacy and safety of polatuzumab vedotin-based regimens in the treatment of diffuse large B-cell lymphoma: A retrospective real-world study (ASH 2025) - "Although R-CHOP regimen has greatly improved the prognosis, 30–40% DLBCL patients develop relapsed/refractory disease. Totally, 109 DLBCL patients receiving Pola-based regimens were enrolled in the study. The median age was 59 years (range, 17 - 80 years), with 52 males (47.7%). There were 60 cases (65.2%) with non-GCB subtypes, 73 cases (78.5%) with Ann Arbor stage III–IV, 28 patients (25.9%) with IPI score >3."

Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CD79B

Reduced-dose whole brain radiotherapy is an effective consolidation strategy for parenchymal-only secondary cns lymphoma (ASH 2025) - "Seven received methotrexate (MTX)-based induction regimens...Additional consolidative systemic therapy was delivered after RT in five patients, which included cytarabine (n=4) and rituximab (n=1)...Two patients experienced extracranial relapse; one of these received salvage therapy with polatuzumab vedotin/bendamustine/rituximab... This cohort suggests that consolidative reduced-dose WBRT may be a valuable consolidation option for certain transplant-ineligible chemo-responsive SCNSL patients, with encouraging and sometimes durable responses. The absence of leptomeningeal and systemic disease at the time of RT may help guide patient selection. These findings support further prospective evaluation and raise the possibility of a new, previous-underexplored role for RT in the management of SCNSL."

B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma

Efficacy and safety of the polatuzumab, acalabrutinib, rituximab, and lenalidomide (Pola-AR2) regimen as first-line therapy in unfit or frail patients with diffuse large B-cell lymphoma (ASH 2025) - No abstract available

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study (ASH 2025) - No abstract available

Clinical • Combination therapy • P1/2 data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma